Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02808975 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

A Phase 4 study of Hidradenitis Suppurativa (HS), sponsored by AbbVie.

Completed
Registry status
Phase 4
Development phase
206
Enrollment target
20
Study locations

NCT02808975 is a Phase 4 study of Hidradenitis Suppurativa (HS) that has completed, run by AbbVie. The registered enrollment target is 206 participants, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02808975, a Phase 4 study of Hidradenitis Suppurativa (HS), has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 4
Development phase
206 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.

Conditions Studied

Hidradenitis Suppurativa (HS)

Interventions

  • DRUG Placebo
  • DRUG Adalimumab

Study Locations (20)

Other

  • Fundacion Valle Del Lili /ID# 151565 - Cali
  • Hospital Pablo Tobon Uribe /ID# 152693 - Medellín
  • Fakult Nem Kralovske Vinohrady /ID# 169173 - Prague
  • Polyclinique Courlancy /ID# 157761 - Reims

California

  • Wallace Medical Group, Inc. /ID# 171289 - Beverly Hills
  • Encino Research Center / T. Jo /ID# 171347 - Encino
  • University of California Irvine /ID# 170054 - Irvine

Louisiana

  • Tulane Univ /ID# 168441 - New Orleans

Massachusetts

  • Beth Israel Deaconess Medical Center /ID# 168438 - Boston

Michigan

  • University of Michigan Hospitals /ID# 200667 - Ann Arbor

North Carolina

  • Univ NC Chapel Hill /ID# 168446 - Chapel Hill

Pennsylvania

  • Penn State Hershey Medical Ctr /ID# 168447 - Hershey

Rhode Island

  • Rhode Island Hospital /ID# 168439 - Providence

Trial Details

FieldValue
Enrollment Target 206 participants
Start Date 2016-07-18
Est. Completion 2019-10-16
Phase Phase 4

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02808975

The ClinicalTrials.gov registry entry for NCT02808975 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (26% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02808975 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Louisiana.

Frequently Asked Questions

What is clinical trial NCT02808975 about?

NCT02808975 is a clinical study titled "Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically". The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.

What is the current status of trial NCT02808975?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 206 participants. The study started on 2016-07-18. Estimated completion is 2019-10-16.

What conditions does trial NCT02808975 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).

What interventions are being tested in trial NCT02808975?

The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG).

Who is sponsoring clinical trial NCT02808975?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02808975 being conducted?

This trial has 20 study locations across California, Louisiana, Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa (HS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa (HS)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.